| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 49 companies in the Life Sciences Tools & Services industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 19, 2024 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 500,000 | $0.98 | $488,650.00 | +0.2% | +23.4% | +47.4% | |
| Jan 18, 2024 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 400,000 | $0.97 | $386,200.00 | +0.2% | +27.4% | +49.8% | |
| Jan 17, 2024 | OPK Opko Health, Inc. | Hsiao Jane Ph D65 | Vice Chairman &CTO | Buy | 150,000 | $0.95 | $142,500.00 | +0.5% | +22.7% | +49.1% | |
| Jan 16, 2024 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 1,000,000 | $0.95 | $954,300.00 | +0.5% | +30.7% | +56.3% | |
| Jan 11, 2024 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 511,531 | $0.94 | $480,378.76 | +0.3% | +33.2% | +54.2% | |
| Jan 8, 2024 | OPK Opko Health, Inc. | Nabel Gary J. | Chief Innovation Officer | Buy | 216,184 | $0.93 | $200,426.65 | +88.9% | +40.0% | +51.0% | |
| Jan 5, 2024 | OPK Opko Health, Inc. | Rubin Steven D68 | Executive Vp-administration | Buy | 10,000 | $0.87 | $8,669.00 | +0.2% | +53.0% | +66.6% | |
| Jan 5, 2024 | OPK Opko Health, Inc. | Pfenniger Richard C Jr62 | Director | Buy | 25,000 | $0.94 | $23,428.80 | +4.1% | +53.0% | +66.6% | |
| Jan 5, 2024 | OPK Opko Health, Inc. | Paganelli John A | Director | Buy | 25,000 | $0.88 | $22,080.00 | +7.0% | +53.0% | +66.6% | |
| Jan 5, 2024 | OPK Opko Health, Inc. | Zerhouni Elias A.50 | Vice Chairman And President | Buy | 550,300 | $0.93 | $514,093.00 | +0.7% | +53.0% | +66.6% | |
| Jan 5, 2024 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 1,500,000 | $0.90 | $1,344,600.00 | +0.7% | +53.0% | +66.6% | |
| Jan 5, 2024 | CSTL Castle Biosciences Inc | Bradbury Daniel69 | Director | Sell | 23,323 | $20.39 | $475,585.20 | -7.2% | +1.1% | +36.2% | |
| Jan 5, 2024 | OPK Opko Health, Inc. | Hsiao Jane Ph D65 | Vice Chairman &CTO | Buy | 150,010 | $0.87 | $130,898.73 | +0.5% | +53.0% | +66.6% | |
| Jan 3, 2024 | NTRA Natera, Inc. | Sheena Jonathan46 | Director, Co-founder | Sell | 6,000 | $60.32 | $361,949.93 | -0.6% | +55.2% | +171.2% | |
| Jan 3, 2024 | WGS Genedx Holdings Corp. | Saad Kareem61 | Chief Transformation Officer | Sell | 105 | $2.58 | $270.89 | -0.4% | +234.4% | +2754.1% | |
| Jan 2, 2024 | EXAS Exact Sciences Corp | Baranick Brian75 | Gen. Mgr., Precision Oncology | Sell | 879 | $73.50 | $64,606.50 | -9.9% | -4.6% | -22.8% | |
| Jan 2, 2024 | EXAS Exact Sciences Corp | Condella Sarah75 | EVP, Human Resources | Sell | 2,000 | $73.50 | $147,000.00 | -2.8% | -4.6% | -22.8% | |
| Dec 29, 2023 | NTRA Natera, Inc. | Brophy Michael Burkes47 | Chief Financial Officer | Sell | 2,292 | $62.69 | $143,685.78 | -1.7% | +46.0% | +155.8% | |
| Dec 28, 2023 | NTRA Natera, Inc. | Sheena Jonathan46 | Director, Co-founder | Sell | 1,447 | $62.22 | $90,029.18 | -0.1% | +45.8% | +158.3% | |
| Dec 28, 2023 | CSTL Castle Biosciences Inc | Maetzold Derek J69 | Pres. &Chief Exec. Officer | Sell | 13,724 | $21.99 | $301,773.57 | -2.3% | -5.1% | +19.6% | |
| Dec 28, 2023 | NTRA Natera, Inc. | Rabinowitz Daniel48 | Sec. And Chief Legal Officer | Sell | 728 | $63.29 | $46,076.79 | -0.4% | +45.8% | +158.3% | |
| Dec 28, 2023 | NTRA Natera, Inc. | Chapman Steven Leonard56 | CEO And President | Sell | 2,604 | $63.29 | $164,813.15 | -1.5% | +45.8% | +158.3% | |
| Dec 27, 2023 | A Agilent Technologies, Inc. | Binns Philip | Senior Vice President | Sell | 2,880 | $139.78 | $402,566.40 | -18.3% | +3.3% | -2.9% | |
| Dec 26, 2023 | CSTL Castle Biosciences Inc | Maetzold Derek J69 | Pres. &Chief Exec. Officer | Sell | 11,869 | $21.95 | $260,465.97 | -1.9% | -5.1% | +23.6% | |
| Dec 21, 2023 | CSTL Castle Biosciences Inc | Maetzold Derek J69 | Pres. &Chief Exec. Officer | Sell | 18,482 | $21.29 | $393,445.87 | -2.8% | -6.6% | +26.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.